As a Free StocksGuide user, you can view scores for all 7,052 stocks worldwide.
17 Analysts have issued a Cullinan Oncology Inc forecast:
17 Analysts have issued a Cullinan Oncology Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -241 -241 |
29%
29%
|
|
| EBIT (Operating Income) EBIT | -241 -241 |
29%
29%
|
|
| Net Profit | -217 -217 |
51%
51%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on 15 September, 2016 and is headquartered in Cambridge, MA.
| Head office | United States |
| CEO | Nadim Ahmed |
| Employees | 111 |
| Founded | 2016 |
| Website | cullinantherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


